Valiant Laboratories Ltd (VALIANTLAB) is currently trading at 56.64 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Valiant Laboratories Limited is a key player in the Active Pharmaceutical Ingredient (API) manufacturing space, specifically focusing on paracetamol production. The company traces its roots back to 1980 and transitioned from a partnership firm to a public limited company in 2021. With an annual installation capacity of 9,000 MTPA, its manufacturing plant is a significant asset situated in Maharashtra. Valiant has expanded its business reach through a subsidiary, Valiant Advanced Sciences Private Limited, established in July 2022 to diversify into new areas. The company raised funds through a public issue, enhancing its capital base and reinforcing growth prospects.

Over the past 52 weeks, Valiant Laboratories Ltd has traded between a low of ₹50.00 and a high of ₹114.72. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Valiant Laboratories Ltd has a market capitalization of approximately 293.50. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Valiant Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -71.16 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 293.50 Cr, Valiant Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Valiant Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Valiant Laboratories Ltd is -71.16. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.